Figure 4. TRAIL⁺ T cells can eliminate residual host APCs.

(A) Tissues from lethally irradiated CBF1 mice were harvested at designated time points and qPCR was performed for DR5. (B) DR5 was assessed by flow cytometry on splenocytes gated on CD11c⁺ DCs, CD11b⁺ macrophages, and B220⁺ B cells. Representative data from 2 independent experiments are shown (n = 3 per group). *P < 0.05. (C and D) Lethally irradiated WT or DR5 KO B6 recipients were reconstituted with 5 × 10⁶ cells per recipient of WT B10.BR TCD BM. Designated groups were treated with 1 × 10⁶ cells per recipient of B10.BR TRAIL⁺ T cells. Survival was monitored (C) and clinical GVHD scores were recorded weekly (D) in a blinded fashion. Graph representative of 2 independent experiments is shown. *P < 0.05; ***P < 0.001; ****P < 0.0001. mLN, mesenteric lymph node.